Literature DB >> 31239333

Effect of time from onset to endovascular therapy on outcomes: the National Acute Stroke Israeli (NASIS)-REVASC registry.

Shlomi Peretz1, Guy Raphaeli2, Natan Borenstein3, Ronen R Leker4, Ran Brauner1, Anat Horev5, José E Cohen6, Gregory Telman7, Hen Halevi3, David Tanne8.   

Abstract

BACKGROUND: Endovascular therapy (EVT) is currently the most effective treatment for emergent large vessel occlusion (ELVO) stroke. Earlier treatment is associated with a better clinical outcome. Our aim was to examine the association between onset-to-EVT (OTE) time and clinical outcomes using real-world nationwide data from the National Acute Stroke ISraeli (NASIS)-REVASC registry.
METHODS: Stroke patients undergoing EVT within the Endovascular Capable Centres (ECCs) in Israel between January 2014 and March 2016 were prospectively included. Several clinical and radiological outcomes were evaluated. The association between OTE time and outcomes was analyzed with logistic regression models using time as a continuous variable and then by OTE groups of <2, 2-4, 4-6, and >6 hours.
RESULTS: 299 patients with acute stroke were included in the analysis. OTE time was significantly associated with favorable outcomes. ORs for each hour of delay in EVT were 0.84 (95% CI 0.71 to 0.99) for significant early recovery, 0.80 (95% CI 0.68 to 0.94) for discharge to home, 0.80 (95% CI 0.66 to 0.95) for freedom from disability at discharge, and 0.78 (95% CI 0.67 to 0.91) for excellent reperfusion (Thrombolysis in Cerebral Ischemia 3). The <2 OTE group was significantly associated with better outcomes than the ≥2 OTE group including significant early recovery (OR 3.3, 95% CI 1.2 to 9.1), discharge to home (OR 3.32, 95% CI 1.3 to 8.5), and excellent reperfusion (OR 4.6, 95% CI 1.3 to 29.5). The same trend was observed for freedom from disability at discharge and 3 months (OR 2.08, 95% CI 0.7 to 5.7 and OR 2.57, 95% CI 0.8 to 8.3, respectively). Only 1% of transferred patients achieved an OTE time of <2 hours.
CONCLUSIONS: Nationwide real-life registry data indicate that benefit from EVT is strongly associated with OTE time and is most prominent within the 'two golden hours' from stroke onset. This time goal may not be applicable in inter-hospital transfer patients. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  endovascular therapy; interhospital transfer; national stroke registry; onset-to-puncture time; real-world data

Mesh:

Year:  2019        PMID: 31239333     DOI: 10.1136/neurintsurg-2019-014928

Source DB:  PubMed          Journal:  J Neurointerv Surg        ISSN: 1759-8478            Impact factor:   5.836


  4 in total

1.  A Critical Assessment of the Golden Hour and the Impact of Procedural Timing in Stroke Thrombectomy.

Authors:  A P Wessell; H D P Carvalho; E Le; G Cannarsa; M J Kole; J A Stokum; T Chryssikos; T R Miller; S Chaturvedi; D Gandhi; K Yarbrough; S R Satti; G Jindal
Journal:  AJNR Am J Neuroradiol       Date:  2020-05       Impact factor: 3.825

2.  Systematic review and meta-analysis of current rates of first pass effect by thrombectomy technique and associations with clinical outcomes.

Authors:  Mehdi Abbasi; Yang Liu; Seán Fitzgerald; Oana Madalina Mereuta; Jorge L Arturo Larco; Asim Rizvi; Ramanathan Kadirvel; Luis Savastano; Waleed Brinjikji; David F Kallmes
Journal:  J Neurointerv Surg       Date:  2021-01-13       Impact factor: 8.572

Review 3.  Artificial Intelligence: A Shifting Paradigm in Cardio-Cerebrovascular Medicine.

Authors:  Vida Abedi; Seyed-Mostafa Razavi; Ayesha Khan; Venkatesh Avula; Aparna Tompe; Asma Poursoroush; Alireza Vafaei Sadr; Jiang Li; Ramin Zand
Journal:  J Clin Med       Date:  2021-12-06       Impact factor: 4.241

4.  Aortic and supra-aortic arterial tortuosity and access technique: Impact on time to device deployment in stroke thrombectomy.

Authors:  Joao Alves Rosa; Rachel Roberts; James Wareham; Robert Crossley; Anthony Cox; Alex Mortimer
Journal:  Interv Neuroradiol       Date:  2020-11-20       Impact factor: 1.764

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.